

INDEX

- AAI. *See* Accelerated Access Initiative
- Abbott, F, 118, 130–1, 139–40
- Abbott, K, 34–5, 42–3, 50–1
- absorptive capacity, 210
- Abuja Declaration, 124–5, 234–5
- Accelerated Access Initiative (AAI), 89, 93–4, 191
- access initiative, 92–4
- accountability, 251–2
- Acquired Immune Deficiency Syndrome (AIDS), 11, 14, 169
- Africa epicenter of, 1–5
- Brazil's epidemic of, 87–9
- ACT. *See* Artemisinin Combination Therapy
- ACWL. *See* Advisory Centre on WTO Law
- ad hoc* mechanism, 72–3
- adequate remuneration condition, 142–3
- adjudicatory body, 36–9
- Advisory Centre on WTO Law (ACWL), 88
- Advisory Opinion Concerning the Reservations to the Convention on the Prevention and Punishment of the Crime of Genocide*, 32–3
- Advisory Opinion of the Legal Consequences of a Wall in the Occupied Palestinian Territory*, 105
- Advisory Opinion on Namibia*, 33–4
- Advisory Opinion on Nuclear Weapons*, 35–6
- Advisory Opinion on South-West Africa*, 46–7
- Advisory Opinion on the Effect of Awards of Compensation Made by the United Nations Administrative Tribunal*, 165–6
- affordability, of ARV drugs, 178–9
- Affordable Medicines Facility for Malaria project, 243
- Africa, 1–5, 9–10
- African Charter on Human and Peoples' Rights, 99, 107
- AIDS. *See* Acquired Immune Deficiency Syndrome
- AIDS Medicine and Diagnostic Services (AMDS), 205
- Alma-Ata Declaration, 162–3
- Alston, P, 206–7
- AMDS. *See* AIDS Medicine and Diagnostic Services
- Amsterdam Declaration to Stop Tuberculosis, 222
- Amsterdam Statement, 122–3
- Andersag, H, 225
- Anglo Ottoman Convention, 37–8
- Anglo-Iranian Oil* case, 37–8
- Annan, K, 10–11, 194–5
- annual income, 185–6
- Anopheles* mosquitoes, 5–6, 225, 231
- anthrax scare, 119, 126
- Anti-Counterfeit Act, 133–4
- Anti-Counterfeiting trade agreements, 253–4
- anti-malaria drugs, 229, 236, 242
- Anti-Retroviral (ARV) Drugs, x–xii, 15–16, 184–5, 206
- affordability of, 178–9
- Brazil's universal access to, 113–14, 121–2
- costs of, 93
- countries obligated to supply, 111–12

- Anti-Retroviral (ARV) Drugs (cont.)
 CSO's role in access to, 122–4
 in developing countries, 92
 Doha Declaration access to, 132–9
 essential medicines, 101, 177
 hard and soft law, xi–xii, 2–3
 history of, 16–20
 as human rights issue, 179–80
 humanitarian access to, 249
 India's generic, 81
 IP rights and manufacturers of, 95–6, 175–8
 Latin American prices of, 138
 Latin America's failure in, 111
 market competition and prices of, 21–3
 mortality rates using, 15–16
 right to health and access to, 106–16
 South Africa's access to, 120–1
 sub-Saharan Africa importing, 138–9
 sustained delivery systems for, 210–11
 technical capacity to deliver, 181–2
 transmission rates reduction and, 19
 TRIPS Agreement access of, 76–9
 Uganda and access to, 91
 UK and provisions on, 173
 UN and access to, 173–5
 UNITAID's financing role for, 180–1
 Zimbabwe's compulsory license for, 137
 anti-retroviral therapy, 250
 Appellate stage, 75
 Arend, A C, 67
 argumental persuasion, 55
 Artemisinin Combination Therapy (ACT), xiii, 238–9
 Article 31 *bis*, 151–4
 adequate remuneration condition in, 142–3
 hard law and, 139–42
 implementation process of, 149–50
 Paragraph 6 agreement and, 148
 TRIPS Agreement and, 130–1, 139
 Article 38, 32
 ARV. *See* Anti-Retroviral Drugs
 Attaran, A, 230
 azidothymidine (AZT), 16–19
 Bacillus Calmette–Guérin (BCG), 217–19, 238–9
 Bahrain, 37
 Barcelona AIDS Conference, 174
 barriers to entry, 42–3
 Bates, R, 193–4
 BCG. *See* Bacillus Calmette–Guérin
 Berejekian, J, 48
 bilateral trade negotiations, 73
 Bill Clinton Foundation HIV/AIDS Initiative, 199
 Bill and Melinda Gates Foundation, 231, 240
 binding agreements, 31, 37–9, 161
 binding nature, of hard law, 40–1
 bio-equivalence exercise, 193–4
 Blue Book, 176
 Boehringer Ingelheim, 22–3
 Bolar provisions, 78, 83–5
 Borchardt, G M, 52
 Botha, J, 113–14
 Boyd, M F, 225–6
 Brazil, 87–9, 113–14, 121–2
 British Medical Research Council Tuberculosis Units, 219–21
 Brittan, L, 120
 bronchial pneumonia, 21–2
 Brownlie, I, 33
 Brundtland, G H, 239
 Burroughs Wellcome Laboratories, 17–18
 Calmert, A, 217
 Cameron, E, 2–0
 CAMR. *See* Canadian Access to Medicines Regime
 Canada, 83–4, 126, 171, 246
 Canadian Access to Medicines Regime (CAMR), 150
 Canadian Generics Medicines Case, 83–5
 case law, 79–89
 CCM. *See* Country Coordination Mechanism
 CD4 count, 188
 Centre for the Treatment and Research on AIDS (TRAC), 150

- CESCR. *See* Committee on Economic Social and Cultural Rights
- Charnovitz, S, 129–30
- Cheever, D, 166
- Chile, 91
- Chinkin, C, 51, 130
- chloroquine, ix, 224–5, 228, 236
- cinchona tree, 224–5
- ciprofloxacin, 21–2
- Civil Society Organizations (CSOs), 119, 122–4, 171–2, 253–4
- Coartem, 231–2
- Cold War, 156
- Commission on Human Rights
 resolution, 168–9, 179–80
- Commission on Macro Economics and Health, 181–2
- Committee on Economic Social and Cultural Rights (CESCR), 97–8
- compulsory adjudication, 74–5
- compulsory licensing, 22–3, 78–9, 135, 148–9
 in Canada, 83–4
 emergency cases and, 134–7
 in South Africa, 86
 in TRIPS Agreement, 86
 Zimbabwe's ARV drugs, 137
- Constitution, of WHO, 157–8
- constructive ambiguity, 146
- constructivism, 50–1, 58–9
- contagious, tuberculosis as, 5
- contracting costs, 79, 85, 207
 hard law and, 44–6, 143–4
- Corfu Channel* case, 130–1
- Correa, C, 108–9
- cost barriers, 192
- counterfeit medicine, 133–4
- Country Coordination Mechanism (CCM), 198, 200–1, 207–8, 250–1
- Crawford, C., 31
- Cruz Bermudez et al. v. Ministry of Health and Social Assistance*, 107
- CSOs. *See* Civil Society Organizations
- customary international law (*opinio juris*), 33, 62–4
- DAI. *See* Drug Access Initiative
- DDT. *See*
 dichlorodiphenyltrichloroethane
 death rates, 230
 Declaration of Commitment on HIV/AIDS, 182
 Declaration of Helsinki, 60
 delegation, 34–5, 50–1
 Deng, F, 61
 developed countries, 145, 147, 188
 generic medicine importing of, 147–8
 pharmaceutical lobbies in, 153–4
 soft law and, 58
 sovereignty costs of, 144–9
 developing countries, 141, 146–7, 173–4, 205
 ARV drugs in, 92
 Doha Declaration obstacles of, 134–7
 DOTS strategy in, 222–3
 essential medicine access in, 145
 generic drugs in, 151–2
 IP rights in, 253–4
 medicine prices in, 22–3
 poverty in, 108–9
 public health in, 72–3, 132–4
 social economic disparities in, 24
 subsidized legal aid in, 88–9
 treatable diseases in, 2–3
 TRIPS Agreement and, 76–8, 90, 123–4
 dialysis treatment, 115
 dichlorodiphenyltrichloroethane (DDT), xiii, 226–8, 235–6
 diplomatic stage, 75
 Directly observed Treatment, Short-course (DOTS), xiii, 220–3
 diseases, 2–3, 12–13, 215–16, 233–4
 endemic, 5–6
 international responses to, 245–6
 of poverty, 6–7
 WHO and, 162–5, 190, 256–7
 Dispute Resolution Understanding (DSU), 74–5, 83, 121–2
 Dispute Settlement Body (DSB), 75
 DNDi. *See* Drugs for Neglected Diseases Initiative
 Doctors Without Borders (Médecins Sans Frontières), xiii–xiv, 18, 150
 Doha Declaration, 127–8, 131, 137–9
 ARVs access through, 132–9
 background of, 119

- Doha Declaration (cont.)
 developing countries obstacles and, 134–7
 flexible approach of, 136
 GFATM and, 205–6
 Paragraph 6 implementation of, 140
 as soft law, 128–31
 TRIPS Agreement not amended by, 118–19
 domestic compliance mechanisms, 42–3
 DOTS. *See* Directly observed
 Treatment, Short-course
 Drug Access Initiative (DAI), 89–92
 drug cocktails, 18–20
 Drugs for Neglected Diseases Initiative (DNDi), 239–40
 DSB. *See* Dispute Settlement Body
 DSU. *See* Dispute Resolution
 Understanding
 Dunoff, J L, 99–100
- East Timor* case, 68
Eastern Greenland case, 38
 EBFs. *See* Extra Budgetary Funds
 EC. *See* European Commission
EC-Bananas case, 109–10
 Economic and Social Council (ECOSOC), 56, 97–8
 economic sanctions, 48–9
 ECOSOC. *See* Economic and Social Council
Edgar Carpio Castro Joffe Mendoza v. Minister of Health and Constitutional Court of Ecuador, 107
 EMR. *See* Exclusive Marketing Rights
 endemic disease, 5–6
 enjoyment approach, 252
 eradication programmes, 27
eradicationitis, 163–4
erga omnes, 35–6
 Essential Interventions, 137
 essential medicines, 205, 215–16, 255–6
 access to, 70–3
 ARV drugs and, 101, 177
 defining, 2, 101
 developing countries access of, 145
 in global health care, 2–3, 8
 IP rights for, 74–5
 pooled procurement systems for, 243
 WHO list of, 193–4
 essential medicines list, 101, 193–4, 250
 Ethiopia, 202
 EU. *See* European Union
 European Commission (EC), xiii
 European Social Charter, 99
 European Union (EU), xiii, 60–1
 Exclusive Marketing Rights (EMR), xiii, 82
 exclusive ownership, 76–7
 exhaustion regime, 136
 Extra Budgetary Funds (EBFs), 177–8
- FDA. *See* Food and Drug Authority
 Fenner, F, 163–4
 Fiddler, D, 12, 157, 160–2
 financial institutions, 195–6, 199
 Finnemore, M, 50–1
 first-line therapy, 15–16
 Fitzmaurice, G, 32–3
 flexibilities, 59–60, 248–9
 flu-like symptoms, 1–6
 Food and Drug Administration (FDA), xiii
 Footer, M, 129
 forum shifting, 141, 246–7
 Framework on Climate Change, 39
 Frank, T, 40–1
 Free-Trade Agreements, 253–4
 funding, 172, 227–8, 241–2
 international, 234–5
 long-term, 205
- GATT. *See* General Agreement on Trade and Tariffs
 GAVI. *See* Global Alliance for Vaccination and Immunisation
 GDF. *See* Global Drug Facility
 GDP. *See* Gross Domestic Product
 General Agreement on Trade and Tariffs (GATT), xiii, 42–3
 General Assembly Resolutions, 33–4, 62–3

- General Comment No. 14, 111–13,
 179, 206, 246
 medicine accessibility in, 101–2
 right to health breach in, 102, 212
 standard of health from, 101
 General Council Resolutions, 49
 generic medicines, 93–4, 187, 193–4,
 250
 active ingredients of, 77
 Bolar provisions and, 83
 developed countries importing of,
 147–8
 in developing countries, 151–2
 in Rwanda, 148–9
 sub-Saharan Africa importing, 138–9
 TRIPS Agreement and suppliers of,
 72–3, 77–8
 Genocide Convention, 41
 GFATM. *See* Global Fund to Fight
 AIDS, Tuberculosis and Malaria
 GFPs. *See* Global Fund Programs
 Global AIDS Reporting Mechanism,
 251–2
 Global AIDS Strategy. *See* Global
 Strategy for the Prevention and
 Control of AIDS
 Global Alliance for Vaccination and
 Immunisation (GAVI), 210
 Global Drug Facility (GDF), 223–4
 Global Eradication Program for
 Malaria, 227, 236
 Global Fund programmes (GFPs), xiii,
 198–202
 Global Fund to Fight AIDS,
 Tuberculosis and Malaria
 (GFATM), xiii, 184–5, 195, 208–9
 background to, 194–8
 contracting costs of, 207
 core indicators of, 251–2
 criticisms of, 199–200
 Doha Declaration and, 205–6
 domestic stakeholders in, 198
 flexibility in, 209–11
 forum shift and, 141
 human resources strengthened by,
 210
 as international financial institution,
 195–6, 199
 long-term model for, 249–50
 multi-sectoral make-up of, 197
 pharmaceutical industry role, 196–7
 pooled procurement systems of, 243
 replenishment exercises of, 199
 right to health and, 211–12
 selection criteria of, 201–2
 soft law and, 212–14
 UK and US donors to, 202–3
 WHO partnership ending with, 196
 global health care, 1–4, 248, 250–3
 accountability in, 251–2
 essential medicine in, 2–3, 8
 programmes, 13
 soft law for, 248, 255–7
 ‘3 by 5’ initiative treatment sites for,
 191
 WHO standards for, 12
 Global Malaria Control Strategy,
 229–30
 Global Malaria Eradication
 Programme, 225–8, 237–8
 global mass vaccination, 217–19
 Global Network of Positive People
 (GNP+), 122–3
 Global Online Forum, 207–8
 Global Partnership Forum, 207–8
 Global Program on HIV/AIDS (GPA),
 14, 169–70
 Global Strategy for the Prevention and
 control of AIDS (Global AIDS
 Strategy), 167–9
 Global Strategy Resolution, 164–5
 Global Tuberculosis Programme, 221
 Global Vaccine Foundation, 240–2
 Globalization and Access to Drugs:
 Implications of the WTO/TRIPS
 Agreement (Red Book), 175–6
 GNP+. *See* Global Network of Positive
 People
 Gonzalez, C L, 162
 Gore, A, 120–1
Government of South Africa v.
Grootbroom, 114–15
 GPA. *See* Global Program on HIV/AIDS
 graduated normativity, 51
 grant applications, 201–2
 Grassi, G B, 225

- Green Light Committee, 223–4
 greenhouse emissions, 39
 Gross Domestic Product (GDP), 15–16
 Guerin, C, 217
 Guidelines on Construction of Core Indicators, 182, 251
 Guzman, A, 40, 50, 55–6
- HAART. *See* Highly Active Antiretroviral therapy
 hard law, 25, 40, 74–5, 153–4
 access initiative accelerated in, 92–4
 adjudicating bodies making, 37
 Article 31 *bis* and, 139–42
 Article 38 and, 32
 ARV drugs and, 2–3
 binding nature of, 40–1
 contracting costs of, 44–6, 143–4
 DAI and, 89–92
 defining, 30–6
 domestic compliance mechanisms in, 42–3
 enforcement ease of, 41–2
 international law through, 30
 jus cogen norms in, 41
 legal positivist perspective on, 30
 new medicine development and, 240–1
 patent problems and, 25–6
 programmes, 89
 right to health as, 98–9
 sanctions abuse and, 47–50, 159
 soft law as precursor to, 68–9
 sovereignty costs of, 46–7, 83
 transaction costs of, 43–4
 TRIPS Agreement as, 74–5
- Haviland, H F, 166
 Health for All, 162–3
 Helfer, L, 141, 247
 Highly Active Antiretroviral therapy (HAART), xiii, 18–20
 Highly Indebted Poor Country Initiative, 187
 HIV. *See* Human Immunodeficiency Virus
 HIV Drug Resistance Surveillance Strategy, 193
- HIV/AIDS, ix–xii, 1, 137–8. *See also*
 Acquired Immune Deficiency Syndrome; Human Immunodeficiency Virus
 ARV drugs and, 2–3, 70–1, 186
 General Assembly Special Session on, 178–80
 Highly Indebted Poor Country Initiative and, 187
 immune system weakened by, 5–6
 international community concern toward, 9–11
 international legal response to, 11–15
 Joint United Nations Program on, 170–1
 malaria and TB with, 6
 patient resistance to treatments for, 219–21
 right to health and, 180
 soft law and programmes for, 169–73
 spread and threat of, xi–xii
 in sub-Saharan Africa, 9, 149–50, 188–9
 Uganda sufferers of, x–xi
 UN partnership fighting, 92
 women impacted by, 6–7
- Horishi Nakajima, 170
 horizontal approach, 162–3
 horizontal forum shifting, 141
 Horwitz, J, 17
 Howse, R, 84
 human immunodeficiency virus (HIV), xiii, 1–5, 9–10, 17–18
 human resources, 210
 human rights, 108–9, 211–12
 ARV drugs as issue of, 179–80
 treaties, 99–100
 TRIPS Agreement and priority of, 110
 UN considering treaties on, 98
 Human Rights Committee, 36, 106–7
 human suffering, 1
 humanitarian access, 249
 humanitarian intervention, 48–9
- ICC. *See* International Criminal Court
 ICCPR. *See* International Covenant on Civil and Political Rights

- ICESCR. *See* International Covenant on Economic Social and Cultural Rights
- ICJ. *See* International Court of Justice
- IDP. *See* Internally Displaced Person
- Ihle, Count, 38
- ILC. *See* International Law Commission
- ILO. *See* International Labour Organization
- IMAI. *See* Integrated Management of Adult and Adolescent Illness
- IMF. *See* International Monetary Fund
- immune system, 1–6
- independent adjudication, 79–80
- India, 80–3
 generic ARVs in, 81
 Patent Act in, 81
 TRIPS Agreement violation of, 81–2
- Industrial Property Law No. 9279, 87
- informal law, 52
- informative soft law, 167–9
- infrastructure, of developing countries, 173–4
- inhibitors, types of, 15–16
- insecticide-treated mosquito nets, 252–3
- instrumentum, 66
- insufficient capacity, 146–7
- Integrated Management of Adult and Adolescent Illness (IMAI), 190–1, 193
- intellectual property (IP), 21, 42–3, 123–4. *See also* IP rights
- Inter-American System, 99
- Internally Displaced Person (IDP), xiii–xiv, 61
- international community, 8–11, 61–2, 215–16
- International Court of Justice (ICJ), xiii, 62, 105, 165–6
- International Covenant on Civil and Political Rights (ICCPR), xiii, 97
- International Covenant on Economic Social and Cultural Rights (ICESCR), xiii, 11–12, 97–8, 112
- Article 12 of, 108
- right to health in, 100–2, 109
- sanctions in, 103
- state obligations in, 104–5
- treaty obligation of, 95–6
- International Criminal Court (ICC), 36–7, 76
- International Criminal Law, 41–2
- international exhaustion, 22
- international financial institution, 195–6, 199
- international funding, 234–5
- International HIV/AIDS Alliance, 201
- International Labour Organization (ILO), xiii–xiv
- international law, 32–3, 54, 56–7, 248–9
 binding agreements in, 37–8
 binding character of, 31
 graduated normativity and, 51
 through hard law, 30
 legal positivist perspective of, 31
 Realist approach to, 49
 sanctions unnecessary in, 54–5
 soft law and, 66–8, 157–8, 207–8
- International Law Commission (ILC), xiii–xiv, 33
- International Monetary Fund (IMF), xiii–xiv
- International Partnership Plus (IPP), 198
- international responses, 11–12, 245–6
- international trade regimes, 56–7, 123
- International Tuberculosis Campaign, 163, 215–19
- interventions, 48–9, 137, 227
- investment protection, 145
- IP. *See* intellectual property
- IP rights, xi–xii, 127–8, 253–4
 ARV manufacturers and, 95–6, 175–178
 for essential medicine, 74–5
 MMV and, 242
 multilateral trade framework and, 73
 TRIPS Agreement and, 134–5
- IPP. *See* International Partnership Plus
- Iranian Oil Case UK v. Iran*, 38
- Iraq, 49
- isoniazid, 220–1
- Japan-Photographic Film Case*, 47
- Jean Chrétien Pledge to Africa*, 150

- Joint United Nations Program, 170–1
jus cogens norms, 41, 206–7
- Kälin, W, 61
 Kaposi's sarcoma, ix
 Kenya, 253–4
 Khan, R, 146
 Klabbers, J, 30, 66
 Kochi, A, 215
 Koh, H H, 54–5
- Latin America, 106, 111, 115–16, 138
 Lauterpacht, H, 32–3
 Law of Treaties, 130–1
 Lazarus effect, 19
 Least Developed Country (LDC),
 xiii–xiv
 Ledger, C, 224–5
 legal aid, 88–9
 legal positivist perspective, 30–1, 66
 legal soft law, 130
 legitimacy, soft law lacking, 64–6
lex ferenda, 33
 LFAs. *See* Local Fund Agents
 licensing agreements, 93–4
 life expectancy, 1–2, 9
 Local Fund Agents (LFAs), 197
 local working of patent, 87–9
 long-term programmes, 249–50
 Love, J, 139
 Luhmann, N, 32
 Lurie, P, 204
 lymphatic filariasis, 256–7
- Maastricht Guidelines, 104
 Mahler, H, 13
 mailbox requirements, 80–1
 malaria, ix–xi, 6, 215–16
 awareness raised for, 233–4
 cheap/free medicines for, 231
 DDT controlling, 235–6
 death rates from, 230
 early treatment of, 224–5
 as endemic disease, 5–6
 global resurgence of, 229
 institutional response to, 229–30
 long-term programme against, 225–6
 medicine access for, 231–2
 re-emergence of, 235–6
 in sub-Saharan Africa, 5–6
 WHA goals against, 230
 WHO battle to eradicate, 225–9
 Malaria Booster Program, 231
 Malaria Eradication Plan, 226–7
 Malaria Eradication Training Centres,
 227
 Malaria Initiative, 27
 Malaria Medicines Venture (MMV),
 239, 242
 Malawesi, J, 173–4
 Maltrex, 81
 Mandela, N, 7
 Mann, J, 164–5, 169–70
 Maputo Declaration, 234–5
Maritime Delimitation Case, 37–8
 market competition, 21–3
 Marrakesh Agreement, 129–31
 mass vaccination programme, 219–21
 Matthews, D, 143–4
 Mayer, T, 50
 McNair, Lord, 29
 MDG. *See* Millennium Development
 Goals
 measurements, 237–8, 252–3
 Médecins Sans Frontières (Doctors
 Without Borders, MSF), xiii–xiv,
 18, 150
 medicines, 8–9, 103–4, 238–41
 cheap/free malaria, 231
 counterfeit, 133–4
 developing countries prices of, 22–3
 first-line therapy with, 15–16
 funding models for, 241–2
 General Comment No. 14 and
 accessibility of, 101–2
 international funding for, 234–5
 IP rights and access to, 127–8
 malaria and access to, 231–2
 pharmaceutical companies and
 prices of, 10–11, 20, 22–3
 piecemeal approach to, 93
 profitability of patented, 145
 reverse-engineered, 138–9
 second-line, 237
 Stop TB Partnership access to,
 223–4

- Medicines Patent Pool, 254–5
 Medicines and Related Substances
 Control Amendment Act, 85–7
 mefloquine, ix
 mental health, 155
 Merson, M, 170
 military action, 49
 Millennium Development Goals
 (MDG), 124–5, 168–9, 211–12, 249
 minimum core approach, 112–13
Ministry of Health and Others (TAC case), 110–11, 114–15
 mission hospital, ix–x
 MMV. *See* Malaria Medicines Venture
 Model List of Essential Medicines, 177–8
 Mooney, L, 193–4
 Mork, T, 166–7
 mortality rates, 9–11, 15–16
 Mörh, U, 65
 mosquito habitat spraying, 235
 MSF. *See* Médecins Sans Frontières (Doctors Without Borders)
 multi-drug-resistant tuberculosis, 237
 Multilateral Trade Agreements, 131
 multilateral trade framework, 73
 multilateral trading regime, 246
 multilateral treaties, 32–3, 68–9
 multinational companies, 73
 My Global Fund, 209–11
 mycobacterium tuberculosis, 5
- NAFTA. *See* North Atlantic Free Trade Association
 Nastios, Andrew, 173–4
 National Cancer Institute, 17–18
 national drug policies, 124–5
 national emergency, 135–6
 National Malaria Control Programmes, 230
 National Tuberculosis Control Programme, 223
 NATO. *See* North Atlantic Treaty Organization
 negotium, 66
 Nevirapine, 19, 110–11, 115
- NGO. *See* Non-Governmental Organization
Nicaragua case, 62
 Nigeria, 202
 nodal governance, 73
 non-binding law, 166–7
 Non-Governmental Organization (NGO), xiii–xiv, 56–7
 non-legal soft law, 130
 non-state stakeholders, 207–8
 Normand, R, 28
 normative activities, 157–8
 normative content, 63–4
 normative value, 203–7
 normativity, 34–6
 North Atlantic Free Trade Association (NAFTA), 42–3
 North Atlantic Treaty Organization (NATO), xiii–xiv, 42–3
 Novartis Malaria Initiative, 231–2
 Novotny, T, 160
 Nuclear Treaty Cases, 38
 nuclear weapons, 35–6, 62
Nuclear Weapons Advisory Opinion, 166
- obligation, 34–5, 50–1
 OECD. *See* Organisation of Economic Cooperation and Development
 OPEC. *See* Organization of Petroleum Exporting Countries
opinio juris (customary international law), 33, 62–4
 oral artemisinin monotherapies, 237
 Organization of African Unity through the Abuja Declaration, 229–30
 Organization of Economic Cooperation and Development (OECD), xiii–xiv
 Organization of Petroleum Exporting Countries (OPEC), xiii–xiv
 ownership, exclusive, 76–7
- Palestinians, 105
 panel stage, 75
 Paragraph 6 agreement, 140–1, 144–9
 Article 31 problem and, 148
 Doha Declaration implementation of, 140

- Paragraph 6 agreement (cont.)
 patented medicine profitability and, 145
 parallel importing, 22
 Paris Convention for the Defence of Industrial Property, 72
 Parkard, R M, 225–7
 Patent Act, 81, 84, 121–2
 patent pre-registration, 80
 patent rights, 25–6, 78–80, 87–9, 121
 exclusive ownership in, 76–7
 human rights approach to, 109
 of pharmaceutical companies, 17, 70–1
 profitability from, 145
 public health considerations of, 75–6
 soft law and rights of, 26
 stockpiling exception in legislation of, 83–4
 system, 23
 TRIPS Agreement and, 21, 65–6, 70–1, 85–7
 Pauwelyn, J, 129
 People living with HIV/AIDS (PLWHA), xiii–xiv
 Pérez de Cuellar, J, 167–8
 Pérez del Castillo, C, 142–3
 Permanent Court of Justice, 38
 persuasion, argumental, 55
 pharmaceutical companies, xi–xii, 92–4, 120–1
 developed countries lobbyist for, 153–4
 GFATM role of, 196–7
 IP rights for, 128
 lobbyists for, 139–40
 malaria medicine from, 231–2
 medicine funding models of, 241–2
 medicine prices and, 10–11, 20, 22–3
 patent rights of, 17, 70–1
 TRIPS Agreement and, 2–3
Pharmaceutical Manufacturers of South Africa v. Government of South Africa, 85–7
 Pharmaceutical Research and Manufacturers for America (PrHMA), xiii–xiv, 128
 physical health, 155
 Piot, P., 20, 89, 171, 257
Plasmodium falciparum MSP-1, 6, 242
Plasmodium parasite, 5–6
 PLWHA. *See* people living with HIV/AIDS
 pneumonia, 21–2
 Pollack, M, 45
 pooled procurement systems, 243
 poverty, 6–8, 108–9, 215–16
 PPP. *See* Public-Private Partnership
 precision, 34–5, 50–1, 100–2
 Presidential Decree on Compulsory Licensing, 87
 Prevention and Control of the Acquired Immune Deficiency Syndrome, 165
 PrHMA. *See* Pharmaceutical Research and Manufacturers for America
 primary health care programme, 13
 private property, 3
 Product Development Partners, 240–1
 Program Coordinating Body, 171–2
 Program for Action, 124–5
 protease inhibitors, 18–20
 Protocol of San Salvador, 107
 public health, 75–6
 in developing countries, 72–3, 132–4
 TRIPS Agreement and, 26, 132–4
 Public Law 105–277, 86
 Public-Private Partnership (PPP), 196
 Qatar Peninsula, 37
 quinine, ix, 224–5
 rational functionalism, 34–5
 R&D. *See* Research and Development
Re: Certification of the Constitution of the Republic of Africa, 105
 Realist approach, 49
 Red Book. *See* Globalization and Access to Drugs: Implications of the WTO/TRIPS Agreement
 regulatory capture, 26, 153–4
 regulatory review, 83–4
 Reid, E, 14
 Reisman, M, 58
 relative autonomy, 67
 replenishment exercises, 199

- reputational loss theory, 55–6
- res. *See* resolution
- Research and Development (R&D), xiii–xiv, 72, 127–8, 238–40
- resistance problems, 237, 255–6
 - drug, 5, 93
 - HIV/AIDS patient, 219–21
- Resolution 36/30, 217–19
- Resolution 58/179, 179
- Resolution 60/62, 179–80
- Resolution 543, 97
- Resolution 1296, 56
- Resolution 1994/24, 171–2
- retrovirus, HIV as, 1–5
- reverse-engineered medicines, 138–9
- rifampicin, 220–1
- right to health, 95–100, 211–12
 - ARV access and, 106–16
 - enforceability and, 102–6
 - General Comment No. 14 breach of, 102, 212
 - as hard law, 98–9
 - HIV/AIDS and, 180
 - under ICESCR, 100–2, 109
 - ICJ case on, 105
 - in Latin America, 106, 115–16
 - in South Africa, 105
 - treatment in, 108
 - violations to, 107
- Robertson, R, 112
- Roll Back Malaria Initiative, 229–31, 234–5
- Ross, R., 225
- Rwanda, 148–54
- Rwanda–Canada case, 246
- Sabrommany v. Minsister of Health Kwa Zulu Natal*, 115
- Sachs, J, 185–6
- sanctions, 40–1, 47, 75, 246
 - economic, 48–9
 - hard law and abuse of, 47–50, 159
 - ICESCR view on, 103
 - international law and, 54–5
 - against Iraq, 49
 - soft law and, 53–6
 - targeted, 48–9
 - in TRIPS Agreement, 95–6
- SAP. *See* structural adjustment program
- Schaffer, G, 45
- second-line drugs, 237
- self-determination, 33–4
- Sell, S, 73, 253–4
- settlement panels, 84
- sexually transmitted diseases, 12–13
- Slaughter, A M, 247
- Smallpox Eradication Program, 163
- Snidal, D, 34–5, 42–3, 50–1
- social economic disparities, 24
- social rights, 103–4
- socialist manifesto, 96
- socio-economic rights, 111–12
- Söderholm, P., 11
- soft law, 25, 53–6, 165–9, 233–4
 - advantages of, 53, 202–3
 - Article 38 and, 32
 - ARV drugs and, xi–xii, 2–3
 - clarification of, 60–2
 - cohesion and consensus for, 57–9, 132
 - complacency from, 253–4
 - compliance in framework of, 182
 - consensus achieved through, 124–5
 - constructivism and, 58–9
 - critiques of, 63
 - defining, 50–3
 - developed countries and, 58
 - developments in, 185–8
 - Doha Declaration as, 128–31
 - establishing, 57
 - EU using, 60–1
 - expectations created by, 62–3
 - flexibility in creating, 59–60
 - forum shifting in, 246–7
 - GFATM and, 212–14
 - for global health care, 248, 255–7
 - hard law precursor and, 68–9
 - HIV/AIDS programmes set up by, 169–73
 - in international community, 61–2
 - international law and, 66–8, 157–8, 207–8
 - law making by treaties and, 59–60
 - legal and non-legal, 130

- soft law (cont.)
 legitimacy lacking in, 64–6
 mosquito habitat spraying and, 235
 non-state actor incorporation and, 56–7
 non-state stakeholders and, 207–8
 normative content vague in, 63–4
 normative value of, 203–7
 patent holder rights and, 26
 standards set for, 250
 state compliance of, 30
 ‘3 by 5’ initiative and, 212–14
 vertical approach and, 162–5
 WHA declaration of, 217–19
 WHO and, 26–7, 159–62
 WTO and, 124–5
 soft treaties, 38–9
 South Africa, 86, 185–6, 202
 ARVs access in, 120–1
 pharmaceutical companies in, 120–1
 right to health in, 105
 South African Constitutional Court, 113
 sovereignty costs, 46–7, 83, 85, 144–9
 Special 301 list, 48
 Special Rapporteur, 99–100
 stakeholders, non-state, 207–8
 states, 30, 54, 103–4
 Doha Declaration agreeing with, 127–8
 ICESCR obligations of, 104–5
 international law and, 54, 56–7
 stavudine, 81
 Stockholm Convention on Persistent Organic Pollutants, 235–6
 stockpiling exception, 83–4
 Stop TB Partnership, 222–4, 234–5, 237–8
 Structural Adjustment Program (SAP), ix–x, xiii–xiv, 191, 204, 210
 sub-Saharan Africa, 138–9, 185–6
 HIV/AIDS in, 9, 149–50, 188–9
 life expectancy in, 1–2
 malaria in, 5–6
 subsidized legal aid, 88–9
 sustainability, 192, 204
 Sustainable Development Goals, 233–4
 sustained delivery systems, 210–11
 TAC. *See* Treatment Action Campaign
 TAC case. *See* Ministry of Health and Others
 targeted sanctions, 48–9
 Tashkent Declaration, 230–1
 Taylor, A, 160
 TB. *See* tuberculosis
 technical capacity, 181–2
 tenofovir, 22–3, 81
 therapy, 18–20, 237–9
 anti-retroviral, 250
 first-line, 15–16
 ‘3 by 5’ initiative, 184–5, 188–94, 205
 background of, 189
 contracting costs of, 207
 criticism of, 193–4
 flexibility in, 209–11
 generic medicine quantities in, 193–4
 health care treatment sites from, 191
 non-state stakeholders’ reliance on, 207–8
 soft law and, 212–14
 sustainability of, 192
 Toope, S, 50–1
 TRAC. *See* Centre for the Treatment and Research on AIDS
 trade sanctions, of WTO, 47
 transaction costs, 43–4
 transmission rates, 19
 treaties, 38–9, 59–60, 95–7
 human rights, 99–100
 multilateral, 32–3, 68–9
 UN human rights, 98
 treatment, 108–9, 115, 189, 224–5.
 See also therapy
 oral artemisinin monotherapies as, 237
 patients’ resistance to, 219–21
 in right to health, 108
 of TB, 217, 219–21
 ‘3 by 5’ initiative and, 188–9, 191
 Treatment Action Campaign (TAC), 122–3
 Triavir, 151–2
 triple-therapy, 18–20
 TRIPS. *See* Trade Aspects of Intellectual Property Rights
 TRIPS Agreement, xiii–xiv, 20–6, 42–3

- Article 7 and 8 of, 135
 Article 28 of, 84, 89
 Article 30 of, 84
 Article 31 of, 130–1, 139
 ARV access in, 76–9
 barriers for access in, 118
 Canadian test of, 126
 case law on, 79–89
 Chile underwriting, 91
 compulsory license in, 86
 countries using exemptions in, 79
 in developing countries, 76–8, 90, 123–4
 Doha Declaration not amending, 118–19
 flexibilities in, 127, 248–9
 generic medicine suppliers and, 72–3, 77–8
 as hard law, 74–5
 history of, 72–4
 human rights priorities and, 110
 independent adjudication and, 79–80
 India's violation of, 81–2
 international exhaustion and, 136
 IP rights and, 134–5
 multilateral trading regime and, 246
 national emergency and, 135–6
 patent rights and, 21, 65–6, 70–1, 85–7
 pharmaceutical companies and, 2–3
 public health prioritized over, 132–4
 sanctioning methods in, 95–6
 settlement panels and, 84
 in South Africa, 86
 sovereignty costs of, 85
 WTO and, 71–2
 tuberculosis (TB), x–xi, xiii–xiv, 6–7, 233–4, 237
 BCG vaccination against, 217–19
 drug-resistant and contagious, 5
 early treatment of, 217, 219–21
 HIV/AIDS and, 6
 in international community, 215–16
 mass vaccination programme for, 219–21
 WHO battle to eradicate, 217–21
 Tuberculosis Initiative, 27
 Tuberculosis Vaccine Initiative, 240–1
 UDHR. *See* Universal Declaration on Human Rights
 Uganda, ix–xi, 91
 UK. *See* United Kingdom
 UN. *See* United Nations
 UN General Assembly (UNGA), xiv, 178–80, 233–4
 UN Treaty Series (UNTS), xiv
 UNAIDS. *See* United Nations Program on AIDS
 UNCTAD. *See* United Nations Conference on Trade and Development
 Understanding on Rules and Procedures Governing the Settlement of Disputes, xiii
 UNDP. *See* United Nations Development Program
 UNFPA. *See* United Nations Population Fund
 UNGA. *See* UN General Assembly
 UNGASS. *See* United Nations General Assembly Special Session
 UNGC. *See* United Nations General Compact
 UNHCR. *See* United Nations High Commissioner for Refugees
 UNICEF. *See* United Nations Children's Fund
 UNITAID, 180–1
 United Kingdom (UK), xiii–xiv, 92, 173, 202–3
 United Nations (UN), 3, 11–12, 98, 165–7
 AIDS response of, 169
 ARV drugs access and, 173–5
 HIV/AIDS partnership of, 92
 WHO within framework of, 156–7
 United Nations Children's Fund (UNICEF), 14
 United Nations Conference on Trade and Development (UNCTAD), xiii–xiv
 United Nations Development Program (UNDP), xiv, 14

- United Nations General Assembly
 Special Session (UNGASS), xiv, 185–8
- United Nations General Compact (UNGC), xiv
- United Nations High Commissioner for Refugees (UNHCR), xiv
- United Nations Office for Project Services (UNOP), 222
- United Nations Population Fund (UNFPA), xiv
- United Nations Program on AIDS (UNAIDS), xiii–xiv, 9–10, 89, 170–2
- United States (US), 86, 202–3, 227–8
- United States Trade Representative (USTR), xiv
- Universal Access Declaration, 193–4
- Universal Declaration on Human Rights (UDHR), xiii–xiv, 28, 68–9, 96
- universal programmes, 206
- UNOP. *See* United Nations Office for Project Services
- UNTS. *See* UN Treaty Series
- US. *See* United States
- USA v. Brazil*, 87–9
- USA v. India*, 80–3
- USTR. *See* United States Trade Representative
- Venezuela, 107
- vertical approach, 162–5, 210–11
- vertical time-limited interventions, 227
- Vienna Convention, 57, 60–1, 130–1
- violations approach, 252
- Volinsky, M J, 161–2
- Voting Procedure* case, 165–6
- waiver agreements, 147
- WB. *See* World Bank
- Weil, P, 66
- Wellens, K, 52
- Western Sahara* case, 68
- WHA. *See* World Health Assembly
- WHO. *See* World Health Organization
- WIPO. *See* World Intellectual Property Organization
- women, 6–7
- World Bank (WB), xiv, 14
- World Declaration on the Control of Malaria and the New Global Malaria Strategy, 233–4
- World Health Assembly (WHA), 11–12, 157–8, 189
- malaria goals of, 230
- non-binding law and, 166–7
- Resolution 55.14 of, 180
- soft-law declaration of, 217–19
- World Health Organization (WHO), xiv, 12–13, 156–7
- ARVs as essential medicines by, 177
- Constitution, 157–8
- cost barriers of, 192
- disease approach of, 162–5, 190, 256–7
- Essential Medicines List of, 193–4
- GFATM ending partnership with, 196
- Global Tuberculosis Programme of, 221
- GPA of, 14
- health standards from, 12
- malaria eradication battle of, 225–9
- physical and mental health and, 155
- soft law and, 26–7, 159–62
- TB eradication battle of, 217–21
- World Intellectual Property Organization (WIPO), xiv
- World Malaria Day, 233–4
- World Trade Organization (WTO), xiv, 3, 47, 124–5
- Article X:7 of, 154
- Marrakesh Agreement establishing, 129–30
- sanctions and compliance with, 75
- TRIPS Agreement and, 71–2
- World Trade Organization Report of the Panel United States*, 131
- Zimbabwe, 10–11, 137, 201–2